Superworth

Macrogenics profit margin MGNX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.

Net margin, 12 months
−8.7%
Operating margin, 12 months
−24.3%
Net margin on a year earlier
+15.5 pts
Peer median
11.6%

Over the twelve months to Jun 30, 2026, Macrogenics kept −8.7% of its revenue as net profit, with an operating margin of −24.3%.

The median for 10 large drugmakers of a similar size is 11.6%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−55.6%−59.1%84.6%
FY2024−44.7%−73.7%91.8%
FY2023−15.4%n/a86.0%
FY2022−78.8%−79.9%n/a
FY2021n/an/a96.6%
FY2020n/an/a100.0%
FY2019n/an/an/a
FY2018n/an/an/a
FY2017−12.4%−14.0%n/a
FY2016−63.7%−65.3%n/a
FY2015−20.0%−20.0%n/a
FY2014−80.2%−80.2%n/a
FY2013−0.4%0.6%n/a
FY201213.1%n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−8.7%+15.5 pts−24.3%
Q1 FY26−49.6%−13.4 pts−49.5%
Q4 FY25−55.6%−11.0 pts−59.1%
Q3 FY25−67.6%+1.5 ptsn/a
Q2 FY25−24.2%n/a−56.3%
Q1 FY25−36.2%+17.4 pts−64.6%
Q4 FY24−44.7%−29.2 pts−73.7%
Q3 FY24−69.1%−110.2 pts−75.8%
Q2 FY24n/an/an/a
Q1 FY24−53.6%+1.6 ptsn/a
Q4 FY23−15.4%+63.4 ptsn/a
Q3 FY2341.1%n/a−88.3%

Against its peers

Companies in Drug Manufacturers - General nearest Macrogenics' size, closest first, today.

Where Macrogenics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Macrogenics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.